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Obesity is associated with a chronic, low-grade, systemic inflammation that may contribute to the
development of insulin resistance and type 2 diabetes. Resveratrol, a natural compound with anti-
inflammatory properties, is shown to improve glucose tolerance and insulin sensitivity in obese
mice and humans. Here we tested the effect of a 2-year resveratrol administration on pro-
inflammatory profile and insulin resistance caused by a high-fat, high-sugar (HFS) diet in white
adipose tissue (WAT) from rhesus monkeys. Eighty mg/day of resveratrol for 12-month followed
by 480 mg/day for the second year decreased adipocyte size, increased sirtuin 1 expression,
decreased NF-κB activation and improved insulin sensitivity in visceral but not subcutaneous
WAT from HFS-fed animals. These effects were reproduced in 3T3-L1 adipocytes cultured in
media supplemented with serum from monkeys fed HFS +/− resveratrol diets. In conclusion,
chronic administration of resveratrol exerts beneficial metabolic and inflammatory adaptations in
visceral WAT from diet-induced obese monkeys.
INTRODUCTION
Over two-thirds of United States adults are overweight or obese, a condition that is assumed
to be produced by excess nutrient intake and possibly by lack of exercise. Obesity is
associated with insulin resistance and an increased risk for type 2 diabetes (Olefsky and
Glass, 2010). Moreover, it is now well established that excess white adipose tissue (WAT) is
related with a state of chronic, low-grade, systemic inflammation, which induces and
sustains insulin resistance (Xu et al., 2003). Activation of the NF-κB pathway has been
shown to directly increase pro-inflammatory cytokine and chemokine gene expression
(Suganami et al., 2007). NF-κB is a major pro-inflammatory nuclear transcription factor that
is sequestered in the cytoplasm in its inactive state in a complex with members of the IκB
family of inhibitor proteins. Following cell activation, IκB kinase β (IKK-β) phosphorylates
IκB, which causes its ubiquitination and proteolytic degradation. This, in turn, frees NF-κB
and enables its translocation to the nucleus where it activates the transcription of target
genes. Hence, pharmacological inhibition of the NF-κB signaling pathway in adipose tissue
may reduce chronic, low-grade, systemic inflammation and confer protection against insulin
resistance and the development and progression of type 2 diabetes.
Resveratrol, a product of red grapes and nuts, has been shown to inhibit NF-κB activation
and expression of inflammatory genes (Heynekamp et al., 2006), thereby improving glucose
tolerance and insulin sensitivity in mice (Baur et al., 2006). The biological effects of
resveratrol in mammals are largely attributed to its ability to activate sirtuin 1 (SIRT1)
(Howitz et al., 2003), a NAD+-dependent deacetylase that regulates a wide range of
biological processes such as gene silencing, aging, cellular differentiation, and metabolism
(Blander and Guarente, 2004). However, it was recently shown that resveratrol might not
activate SIRT1 directly, but rather exert its effects on SIRT1 through inhibition of cAMP-
degrading phosphodiesterases (Park et al., 2012), although direct SIRT1 activation is not
completely excluded (Dai et al., 2010). Regardless of the mode of activation, SIRT1-
mediated deacetylation of p65 subunit (RelA) of NF-κB, at lysine 310, contributes to the
down-regulation of NF-κB transcriptional activity and leads to decreased inflammatory
response (Yeung et al., 2004) and improved insulin sensitivity in adipocytes and
macrophages (Yoshizaki et al., 2009; Yoshizaki et al., 2010).
A number of recent studies have determined that short-term resveratrol supplementation (4-6
weeks) decreases inflammation (Ghanim et al., 2010; Timmers et al., 2011) and improves
insulin sensitivity and metabolic function in adults who are obese, have type 2 diabetes, or
older individuals with impaired glucose tolerance (Timmers et al., 2011; Crandall et al.,
2012; Brasnyó et al., 2011). In contrast, no improvement in metabolic profile was noted
after a 12-week resveratrol supplementation in nonobese women with normal glucose
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tolerance (Yoshino et al., 2012) while promising effects on glucose tolerance has been
reported in primates fed chronically a standard diet supplemented with resveratrol (Marchal
et al., 2012). Data from our laboratory have also shown beneficial effects of long-term
resveratrol administration in non-human primates fed a high-fat, high-sugar (HFS) diet, a
diet formulated to encourage obesity as well as chronic low grade inflammation and insulin
resistance. Specifically, resveratrol prevented β-cell dedifferentiation in pancreas (Fiori et
al., 2013) and conferred protection against inflammatory profile of aortic wall from rhesus
monkeys fed HFS diet (Mattison et al., unpublished data). Despite these advances, there are
no studies showing the effectiveness of chronic administration of resveratrol for improving
insulin sensitivity, and metabolic and inflammatory profile altered by HFS diet in WAT
from a non-human primate model. Then, the aim of the present study was to establish the
effect of a 2-year resveratrol supplementation on the pro-inflammatory profile and insulin
resistance caused by HFS diet in subcutaneous and visceral WAT from rhesus monkeys, a
species close to human.
RESULTS
Rhesus monkey characteristics
Table S1 shows the characteristics pre-intervention (baseline) of 24 rhesus monkeys
included in this study. The monkeys assigned to diets did not differ in age, weight, waist,
hip, lipids and glucose metabolism parameters. Post-intervention, previous data (Fiori et al.,
2013) have proven no metabolic dysregulation at 24 months of dietary interventions, based
on fasting insulin and glucose levels. However, an increase in insulin area under the curve
(AUC) from intravenous glucose tolerance test (IVGTT) and a decrease in insulin sensitivity
index (ISI) was shown with the HFS +/− resveratrol (Resv) diets compared to baseline,
consistent with a weight gain and insulin resistance (Fiori et al., 2013). In the present study,
an additional analysis was carried out in order to determine the resveratrol effects at
systemic level after 24 months of dietary intervention. Since the animals at pre-intervention
state were fed with a standard diet (SD) and non-significant differences were observed
between monkeys fed with SD at baseline (SDb) and post-intervention, we considered the
baseline measurements for the experimental animals to represent the control state (Table 1).
Post-intervention, HFS +/− Resv diets increased the waist and hip measurements (P < 0.05)
when compared with SDb control group. An increase in LDL plasma levels, a characteristic
associated to insulin resistance, was observed in monkeys fed HFS diet (P = 0.011) respect
to animals in SDb control group.
Changes in gene expression of subcutaneous and visceral WAT by resveratrol
To examine possible effects of Resv in adipose tissue, we performed a genome-wide
microarray analysis on subcutaneous WAT from rhesus monkeys at the start of the
experiment (SDb) and after a two-year treatment with HFS +/− Resv diet (Figure 1).
Analysis of the transcript profile revealed that a significant proportion of the genes whose
expression was modified by HFS were shifted in the opposite direction in response to Resv
supplementation (Figure 1A). Further analysis showed a highly related gene signature when
comparing the Z-score of a given gene from Resv to either HFS (Resv_HFS) or SDb
(Resv_SDb) (Figure 1A). Parametric analysis of gene-set enrichment (PAGE) was then
used to highlight functional pathways most affected by the various dietary regimens.
Focusing in gene categories related to immune responses and inflammation (i.e.,
inflammatory response, tumor necrosis factor receptor activity, chemokine activity, and
others), the Z-score of a given GO term showed striking differences when comparing Resv
to HFS (Resv_HFS) vs. HFS to SDb (HFS_SDb) (Figure 1B). Ingenuity pathway analysis
revealed diet-induced alterations in inflammation-related biological functions in
subcutaneous WAT (Table S2).
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The fact that our animal research protocol did not allow for the collection of visceral WAT
at the onset of the experiment has prevented us to compare the effect of HFS +/− Resv diet
vs. SDb in this fat depot. Nevertheless, visceral WAT from 2-year SD group was collected
and used for subsequent comparisons. Consistent with the results obtained in subcutaneous
fat, Resv supplementation elicited a genome-wide expression profiling that was opposite to
that observed with HFS feeding (Figure 1C). A clear overlap between the genes whose
expression was significantly altered by Resv supplementation compared to either SD
(Resv_SD) or HFS (Resv_HFS) is shown in the Venn diagram (Figure 1D). Using PAGE
analysis, we focused on select genesets known for their susceptibility to Resv (e.g.,
Electron_Transport_Chain, Proteasome, Aged_Rhesus_Up, TollPathway, and others), and
found a number of genesets that were regulated in opposite directions by HFS_SD vs.
Resv_HFS in visceral WAT (Table S3). Indeed, scatter plot of gene expression values in
HSF_SD within the ‘stresspathway’ geneset showed strikingly opposite changes as
compared to Resv_HFS (Figure 1E). Moreover, the transcriptional effect of HFS feeding
appears to have intrinsic fat depot-specific difference in the regulation of some genesets,
including Proteasome and Aged_Rhesus_Up (Table S3). These data indicate that HFS
feeding +/− Resv supplementation elicits a set of transcriptional changes that is likely to
shape the distinct depot-specific responses in rhesus monkeys.
Resveratrol increases the number of small adipocytes in visceral WAT
A H&E staining of WAT showed non-significant differences in the mean size of adipocytes
and adipocyte frequency distribution when subcutaneous WAT from monkeys assigned to
HFS diet was compared to that of HFS + Resv diet group (Figure 2A). However, the
analysis of adipocyte frequency distribution in visceral WAT showed a distribution change
toward smaller adipocytes in the HFS + Resv diet-fed monkeys compared with HFS diet-fed
group. As a result, a significant difference in the mean size of adipocytes between both
groups was observed (P = 0.032) (Figure 2B).
Increased SIRT1 protein levels in visceral WAT by resveratrol supplementation
SIRT1 protein expression was measured in visceral and subcutaneous WAT after dietary
intervention (Figure 2). No change in SIRT1 protein levels was found in subcutaneous fat
between the groups (Figure 2C). However, HFS + Resv diet induced a significant increase
of SIRT1 protein levels in visceral fat when compared to HFS diet (P = 0.010) (Figure 2D).
Resveratrol inhibits NF-κB activation and expression of target genes in visceral WAT
A decrease in NF-κB activation, as evidenced by a substantial increase of IκBα protein
levels (P = 0.003) (Figure 3A), and reduction of NF-κB phosphorylation (P = 0.02) (Figure
3B) and acetylation (P = 0.05) (Figure 3C) was found in visceral fat of rhesus monkeys fed
with HFS + Resv diet as compared with HFS diet. Inhibition of the NF-κB signaling by
Resv was accompanied by a decrease of NF-κB target gene expression (IL-6, P = 0.05;
IL-1β, P = 0.048) (Figure 3D). However, regulation of NF-κB in the subcutaneous adipose
tissue was refractory to Resv supplementation (Figure 3E-F).
To extend the results obtained in visceral fat, we next quantified the circulating levels of
several inflammatory pathway components and found the concentration of pro-inflammatory
IL-1β to be significantly higher after consumption of a HFS ± Resv diets compared to SDb
control (P < 0.05) (Table S4). Non-significant differences between groups were observed in
the other variables analyzed (IL-6, C-reactive protein (CRP), TNF-α and Adiponectin)
(Table S4).
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Resveratrol modulates the expression of insulin-signaling protein markers in visceral WAT
An increase of IRS-1 protein levels (P = 0.05) (Figure 4A), a decrease of Akt serine 473
phosphorylation (P = 0.003) (Figure 4B) and an increase in the content of insulin-
responsive GLUT4 glucose transporter (P = 0.033) (Figure 4C) were observed in visceral
fat depot from fasted monkeys on HFS + Resv group as compared to HFS diet controls. It is
important to note that chronic stimulation of Akt in adipocytes and transgenic mice
overexpressing constitutively active Akt elicit negative feedback on insulin signaling (Ozes
et al., 2001; Nagoshi et al., 2005). Therefore, reduction in phosphoactive Akt in adipocytes
of fasted monkeys maintained on HFS + Resv diet vs. HFS supports the notion of an
improved insulin sensitivity in visceral WAT from the HFS + Resv diet-fed animals.
In unstimulated fat and muscle cells, GLUT4 is sequestered intracellularly in part by binding
the Tether, containing a UBX domain, for GLUT4 (TUG) protein (Bogan et al., 2003).
Insulin stimulates TUG endoproteolytic cleavage to mobilize intracellular GLUT4 storage
vesicles to the plasma membrane, an action that allows glucose to enter the cells by
facilitative transport (Bogan et al., 2012). Here, TUG protein levels tended to be higher in
HFS + Resv group compared to HFS group, although these differences did not reach
statistical significance (Figure 4D).
Refractoriness of visceral WAT mitochondrial to resveratrol treatment
To test if the Resv-mediated expression of classical markers of insulin signaling pathway
was associated to an effect of this polyphenol in visceral WAT mitochondria, we analyzed
mitochondrial content (citrate synthase activity, mRNA expression for cytochrome b (CytB),
NADH dehydrogenase 1 (ND1), ND2, ND5 and ND6, and NADH dehydrogenase
(ubiquinone) 1 alpha subcomplex, 9 (NDUFA 9) protein levels), mitochondrial biogenesis
(mRNA expression for PPARγ co-activator 1 (PGC-1α) and dimethyladenosine transferase
2 mitochondrial (TFB2M)) and oxidative stress (H2O2 and lysine 4-hydroxynonenal (HNE)
levels) in this fat depot from rhesus monkeys after dietary intervention. Non-significant
changes between HFS and HFS + Resv diet were observed in these parameters (Figure S1).
Serum from resveratrol-treated monkeys elicits anti-inflammatory effects and improves
insulin signaling in 3T3-L1 adipocytes
The inflammatory profile of fully-differentiated 3T3-L1 adipocytes was assessed after a 24-
h incubation with media containing serum from monkeys fed with SD, HFS and HFS + Resv
diets for 24 months. The results indicated an increase in SIRT1 protein level (P < 0.05)
(Figure 5A) and decrease in NF-κB phosphorylation (P < 0.05) (Figure 5C) after treatment
of 3T3-L1 adipocytes with serum from animals fed SD or HFS + Resv diet as compared to
HFS serum. Moreover, a decrease in NF-κB target gene expression (IL-6, P = 0.016) was
also observed when 3T3-L1 adipocytes were incubated in media containing HFS + Resv
serum vs. HFS serum (Figure 5D). A trend toward lower IL-6 mRNA was found with SD
serum vs. HFS serum (P = 0.056).
This reduction of the pro-inflammatory profile by the HFS + Resv serum may correlate with
an improvement in insulin sensitivity. Control experiments showed no difference in IRS-1
protein levels upon treatment of 3T3-L1 adipocytes with the three serums at baseline
(Figure 6A). However, a significant effect of time (P = 0.017) and the interaction -diet and
time- (P = 0.041) in Akt activation was found when 3T3-L1 adipocytes that were pretreated
with monkey serum for 24 h were stimulated with insulin for 30 min. Specifically, the
duration of insulin-induced Akt phosphorylation was markedly longer when 3T3-L1
adipocytes were pretreated with serum from HFS diet group as compared to that of SD and
HFS + Resv diet (Figure 6B). Moreover, a significant increase in the number of cells
expressing GLUT4 at the plasma membrane (P < 0.05) (Figure 6C) and greater insulin-
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induced cell surface GLUT4 labeling (P < 0.05) (Figure 6D) were observed when 3T3-L1
adipocytes were incubated with SD or HFS + Resv serum as compared with HFS serum.
DISCUSSION
Obesity is recognized as a chronic, low-grade, systemic inflammation, which contributes to
the development of insulin resistance (Gustafson et al., 2007). Approaches aimed to reduce
adipose tissue inflammation may be effective at improving insulin resistance. In this sense
the polyphenol Resv has been shown to improve glucose tolerance and insulin sensitivity in
diet-induced obese mice (Baur et al., 2006; Lagouge et al., 2006) and in obese people
(Timmers et al., 2011). Here, gene expression studies and pathway analyses revealed that
Resv supplementation partly protect adipose tissue from transcriptional changes that lead to
activation of pro-inflammatory and stress responses in rhesus monkeys upon HFS feeding.
Some of the transcriptional changes induced by a 2-year HFS +/− Resv supplementation
were fat depot-specific, which may be the cause of the observed alterations in visceral vs.
subcutaneous WAT after dietary intervention. To our knowledge, we show for the first time
that long-term Resv supplementation reduced adipocyte size, increased SIRT1 protein
levels, and decreased both NF-κB activation and several inflammatory markers in visceral
WAT of diet-induced obese rhesus monkeys. Moreover, chronic administration of Resv
elicited an appropriate expression of classical markers of insulin signaling pathway in
visceral WAT. The fact that these effects were partially reproduced in 3T3-L1 adipocytes
incubated with media supplemented with serum from monkeys fed HFS +/− Resv indicated
that adipocytes may contribute to the development of these metabolic and inflammatory
adaptations.
Resveratrol has received considerable attention for its ability to activate SIRT1, an enzyme
that deacetylates a range of substrates including PGC-1α, uncoupling protein (UCP)-2, NF-
κB and FoxO1, which, in turn, results in a profound effect on glucose homeostasis and
insulin secretion in rodents (Rodgers et al., 2005, Kitamura et al., 2005, Moynihan et al.,
2005). In adipose tissue, SIRT1 represses adipocyte differentiation and expression of genes
controlled by PPARγ (Picard et al., 2004), while increasing FoxO1-mediated adiponectin
expression in adipocytes (Qiao and Shao, 2006) and PCG-1α–mediated adaptative
thermogenesis in brown adipose tissues (Puigserver et al., 1998). Moreover, SIRT1 has been
implicated in the negative regulation of the NF-κB inflammatory response in 3T3-L1
adipocytes (Yoshizaki et al., 2009). Because of the growing evidence that links chronic low-
grade inflammation to the development of insulin resistance (Cai et al., 2005) and the ability
of SIRT1 at reducing inflammation and improving glucose tolerance in mice (Ramsey et al.,
2008), it was imperative to extend these findings to a species close to human. Toward this
end, we studied the effect of chronic administration of Resv on the HFS diet-induced pro-
inflammatory state and insulin resistance in rhesus monkey WAT and found that significant
changes in adipocyte size, SIRT1 expression and NF-κB activity were observed in visceral
WAT but not subcutaneous WAT, indicative of functional differences among fat depots
(Coon et al., 1992; Gastaldelli et al., 2002). Consequently, the ability of Resv to regulate
NF-κB target gene expression was examined in visceral WAT. A decrease in IL-6 and IL-1β
mRNA levels was observed in HFS + Resv group when compared to HFS-fed animals,
consistent with earlier observations showing that Resv reduces pro-inflammatory cytokine
expression in cultured mouse and human adipocytes (Gonzales and Orlando, 2008; Kennedy
et al., 2009) and in rodent WAT (Rivera et al., 2009). These findings in our study were
associated with a reduction in the inflammatory profile of aortic wall (Mattison et al.,
unpublished data) from monkeys assigned to HFS + Resv diet, without changes in
circulating pro-inflammatory cytokines levels. This latter result could be due to a variety of
reasons as duration of dietary intervention and/or the effect of Resv in other contributors of
systemic inflammation (e.g. liver and muscle).
Jimenez-Gomez et al. Page 6
Cell Metab. Author manuscript; available in PMC 2014 October 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Adipose tissue is composed of mature adipocytes and the stromavascular fraction that
contains preadipocytes, blood cells, and macrophages. IL-1β and IL-6 are produced by
adipocytes (Trayhurn and Wood, 2005) and the increase in inflammatory response following
SIRT1 depletion in 3T3-L1 adipocytes is reversed upon cell treatment with SIRT1 activators
(Yoshizaki et al., 2009). In support of the latter study, we observed that 3T3-L1 adipocytes
treated with media supplemented with serum from monkeys fed with HFS + Resv diet had
higher SIRT1 protein level but lower NF-κB phosphorylation and IL-6 mRNA expression
when compared to the HFS-fed animals. Taken together, these data indicate that adipocytes
contribute, at least partly, to the beneficial effects of Resv in visceral WAT.
Studies conducted in healthy obese men (Timmers et al., 2011) and patients with type 2
diabetes (Brasnyó et al., 2011) demonstrate that 4-week Resv administration exerts
beneficial effects on systemic insulin sensitivity. However, others performed in subjects
with impaired glucose tolerance (Crandall et al., 2012) and normal weight healthy
individuals (Ghanim et a, 2010) have shown non-significant changes in fasting glucose or
insulin levels after acute resveratrol supplementation (4-6 weeks). These contradictory
results warrant additional studies on the effect of long-term resveratrol supplementation.
Long-term treatment of adipocytes with IL-6 or IL-1β inhibits IRS-1 and GLUT4 expression
(Rotter et al., 2003; Jager et al., 2007). Likewise, lower IRS-1 and GLUT4 content is
observed in adipocytes from patients with type 2 diabetes (Carvalho et al., 1999; Garvey et
al., 1991) and in insulin-resistant subjects (Carvalho et al., 1999; Shepherd and Kahn, 1999).
Moreover, there is emerging evidence showing that prolonged activation of Akt leads to
negative feedback of insulin signaling (Ozes et al., 2001; Nagoshi et al., 2005), possibly
through p65/RelA-mediated increase in the phosphorylation and expression of Akt (Meng
and D'Mello, 2003). We report that long-term Resv supplementation improved expression of
classical markers of insulin signaling cascade in visceral adipose tissue of HFS-fed rhesus
monkeys through increased IRS-1 protein levels, lower chronic activation of Akt and higher
GLUT4 protein content. This effect in visceral WAT was asssociated with a preservation of
pancreas morphology without improvement of insulin sensitivity at the systemic levels
(Fiori et al., 2013). This latter finding may be partly explained by the fact that 2-year
resveratrol supplementation may not be sufficient to observe systemic changes in glucose
homeostasis in rhesus monkeys. In this sense, Marchal et al. (Marchal et al., 2012) did not
observe differences in insulin sensitivity and glycemia markers between grey mouse lemurs
fed standard diet and those fed with standard diet supplemented with resveratrol at 21
months of dietary intervention. However, after 33 months, resveratrol decreased glycemia
after the oral glucose loading and HOMA-IR index compared with standard diet in these
non-human primates. Finally, although Resv potently increases mitochondrial function and
biogenesis through PGC-1α in muscle and brown adipose tissue and confers protection
against diet-induced obesity and insulin resistance in mice (Lagouge et al., 2006), we did not
observe an improvement of mitochondrial content in visceral WAT of HFS + Resv diet-fed
rhesus monkeys, indicating a possible tissue-specific effect of Resv. In agreement with us,
Lagouge et al. (Lagouge et al., 2006) did not observed changes in mitochondrial biogenesis
in the heart, despite the coexpression of PGC-1α and SIRT1. Likewise, Chabi et al. (Chabi
et al., 2009) found that liver, and to a lesser extent adipose tissue, from rats shows high
levels of SIRT1 activity, despite having low PGC-1α protein content, which are in
accordance with the reported role of SIRT1 in the activation of lipolysis and
gluconeogenesis (Picard et al., 2004; Rodgers et al., 2005), but do not indicate that the
SIRT1 expression pattern is related to the oxidative capacity of a given tissue. Alternatively,
long-lived species, such as primates and humans, may have different bioenergetics response
to Resv compared to short-lived species (e.g. mice and rats).
To demonstrate that Resv effectively improves insulin sensitivity in WAT, we studied the
effects of this compound in 3T3-L1 adipocytes and found that the serum from rhesus
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monkeys fed with HFS + Resv diet normalized insulin-induced Akt activation, increased the
number of cells expressing GLUT4 and the quantity of this glucose transporter at the plasma
membrane in response to an acute insulin challenge. However, Resv was also found to
increase the insulin-stimulated phosphorylation of Akt in 3T3-L1 adipocytes (Kang et al.,
2012). Difference in experimental conditions (e.g., insulin concentration; monkey serum vs.
inflammatory conditioned media from lipopolysaccharide-stimulated RAW264.7 cells; Resv
administered to monkeys for 2 years vs. Resv addition to the inflammatory conditioned
media) could ultimately account for the opposite results between the two studies. It is
interesting that Resv reduces serine phosphorylation of IRS-1 and a subsequent degradation
of the protein through inhibition of Akt and JNK activity in insulin-resistant muscle cells
(Frojdo et al., 2011).
In conclusion, our data suggest that before evidence of dysglycemia is uncovered, the
chronic administration of Resv produces beneficial metabolic and inflammatory adaptations
in visceral WAT of a diet-induced obese non-human primate model. In addition, we
demonstrate that adipocytes are partly responsible for the favorable adaptations produced by
Resv in visceral WAT. Although lifestyle changes and pharmacotherapy are the primary
intervention to improve insulin resistance, they are difficult to follow and maintain and may
be too late as changes predisposing to diabetes could have already happened in pancreas and
peripheral tissues. Since Resv was well tolerated at the tested concentrations, long-term
Resv supplementation may provide a safe approach to reduce the chronic inflammatory
properties associated with obesity while restoring insulin responsiveness in visceral WAT.
EXPERIMENTAL PROCEDURES
Animals
Twenty-four adults (7-13 years old) male rhesus monkeys (Macaca mulatta) were housed at
the NIH Animal Center, Poolesville, MD, a center fully accredited by the American
Association for Accreditation of Laboratory Animal Care. All procedures were approved by
the Animal Care and Use Committee of the NIA Intramural Program. Details of animal care
are provided in Supplemental Material.
After baseline assessment, the animals were subjected to a dose escalation study of 2-year of
duration. Monkeys were quasi-randomized into one of three groups: HFS diet + Resv
(n=10); HFS diet + placebo (n=10); Standard diet (SD) (n=4). The three diets were
isoenergetics (~52 kcal / Kg body weight per day). The SD was a commercially available
closed formula monkey chow (TestDiet® #5038, Purina Mills, Richmond, IN); 13% of kcal
in fat and 2.24% sucrose by weight. The main sources of macronutrients in the SD were as
follows: Protein— soy meal, corn; Fat— porcine fat, corn; Carbohydrate— corn,
wheatmiddlings. The HFS diet was a specially formulated purified ingredient diet with 42%
of kcal in fat and approximately 27% sucrose by weight (Custom formula #07802, Harlan,
Teklad, Madison, WI). The main sources of macronutrients in the HFS diet were as follows:
Protein —casein, lactalbumin; Fat —milk fat, soybean oil; Carbohydrate —sucrose and
maltodextrin. Macronutrient composition in both diets was: 1) SD diet: 18.2% of kcal in
protein, 13.1% of kcal in fat, 68.7% of kcal in carbohydrate, 2.24% sucrose; 2) HFS diet:
15.8% of kcal in protein, 42.3% of kcal in fat, 41.9% of kcal in carbohydrate, 27% sucrose.
The monkeys were gradually switched to HFS diet over a 3-week period. Both groups
received 2 meals per day in allotments that represented ad libitum feeding. Resv (resVida®)
was supplied by DSM Nutritional Products (Parsippany, NJ). Each monkey in the HFS +
Resv group received a total daily dose of 40 mg twice a day. Details of calculation of the
dose are provided in Supplemental Material. No adverse effects to Resv were evident.
Monkeys in non-Resv group received a placebo treat. After 1-year, the Resv dose was
increased to 240 mg twice a day to document a dose effect. Again, no adverse effects were
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evident. An increase of serum trans-Resv and its O-sulfated metabolite concentration (P <
0.05) was observed with the dosage increments (40 vs. 240 mg twice daily) in HFS + Resv
group (Figure S2).
Blood and adipose tissue sample collection
In monkeys anesthetized with ketamine (7-10mg/kg, intramuscular), fasting blood samples
were obtained by venipuncture of the femoral vein at 0, 9 and 24 months of dietary
intervention and subcutaneous adipose tissue was collected via an open incision at the
ventral midline of the abdomen at 0 month of dietary intervention. Adipose tissue was
obtained at 24 months of dietary intervention after the fasting monkeys were anesthetized
with a lethal dose of sodium pentobarbital (50 mg/kg, intraperitoneal). Once deeply sedated,
the monkeys were perfused with cold lactated Ringer's solution until death. A section of
subcutaneous adipose tissue was collected via an open incision at the ventral midline of the
abdomen. The peritoneal cavity was then exposed and visceral adipose tissue was collected
from the omentum. Samples were stored in cryovials, flash frozen in liquid nitrogen, and
stored at −80 °C until assayed.
Biochemical determinations
Total cholesterol, LDL-C, HDL-C were obtained by a VAP test by Atherotech Diagnostics
Lab (Birmingham, AL). Serum fasting insulin was determined by ELISA using a
commercially available kit (Mercodia, Inc., Uppsala, Sweden). Fasting glucose was
determined from whole blood with an Ascensia Breeze 2 Blood Glucose Meter (Bayer
Healthcare LLC, Mishawaka, IN). Serum trans-Resv and trans-Resv-3-O-sulfate
concentration was measured by a chromatography and mass spectrometry method as
described in Supplemental Material.
3T3-L1 cell culture and in vitro experimental setups—Mouse 3T3-L1 fibroblasts
(American Type Culture Collection, Manassas, VA) were cultured and differentiated toward
adipocytes as previously described (Student et al., 1980) with modifications. See
Supplemental Material for further details.
For treatments, 3T3-L1 adipocytes were cultured with high glucose DMEM containing 4
mM glutamine and 1.5 g/L NaH2CO3 and supplemented with 10% pooled monkey serum
from either the SD, HFS or HFS + Resv group. After a 24-h incubation period, cells were
treated with 100 nM insulin for 30 min. 3T3-L1 adipocytes were harvested for RNA and
protein determination and examined also for GLUT4 translocation by immunocytochemistry
at the time points indicated in Figures.
Protein extraction—50-100 mg of adipose tissue were thawed by adding 250 μL of cold
urea/thiourea buffer (7 M urea (Sigma-Aldrich), 2 M thiourea (Sigma-Aldrich), 4% CHAPS
(USB Affymetrix, Santa Clara, CA), 45 mM Tris pH 7.4 (Sigma-Aldrich), 60 mM
dithiothreitol (Sigma-Aldrich) and protease and phosphatase inhibitors (Sigma-Aldrich)).
Cells were mechanically disrupted and briefly sonicated. Samples were incubated for 15 min
at 35 °C and cooled on ice for 10 min. The homogenate was then centrifuged (15 min, 10
000 × g, 4 °C) and the aqueous phase between the upper lipid p hase and lower cellular
debris phase was collected. Extensive delipidation was accomplished by tri-n-
butylphosphate-acetone-methanol (Sigma-Aldrich) precipitation (Gesta et al., 2006).
Precipitated proteins were resuspended in 80 μL of urea/thiourea buffer, and the Lowry
assay method (Bio-Rad, Hercules, CA) was used to determine protein concentration.
For immunoprecipitation and determination of GLUT4 and TUG protein content, visceral
adipose tissue was mechanically lysed and briefly sonicated in RIPA buffer supplemented
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with EDTA and EGTA (Boston BioProducts, Ashland, MA), protease and phosphatase
inhibitors (Sigma-Aldrich) and 0.1 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich).
3T3-L1 adipocytes were also lysed using the same buffer. The homogenate was then
centrifuged and the aqueous phase was collected between the upper lipid phase and lower
cellular debris phase. The Bradford assay method (Bio-Rad) was used to determine protein
concentration.
Western blot and Immunoprecipitation—Protein expression by western blot and
acetylated NF-κB quantification by immunoprecipitation were performed according to
standard procedures as described in Supplemental Material. Ponceau S staining was selected
as a loading control (Romero-Calvo et al., 2010), because the values of integrated
densitometric peak areas correlated with NF-κB protein levels when serial dilutions of a
visceral WAT protein sample were analyzed (r2 = 0.99; Figure S3).
Gene expression—Microarray and real-time PCR techniques were carried out according
to standard procedures to determine the effects of Resv on gene expression of 3T3-L1
adipocytes and WAT from rhesus monkeys. Full methodological details are provided
described in Supplemental Material. The primer sequences used in real-time PCR are
summarized in Table S5.
Histology—H&E staining of paraffin-embedded tissue sections was performed by
Histoserv, Inc. (Germantown, MD). Samples were visualized under an optical microscope
(DAS Mikroskop Leitz DMR; Leica, Wetzlar, Germany) and image stacks were analyzed
with ImageJ software. To evaluate mean size and adipocyte frequency distribution, the
surface area of a minimum of 370 cells per group was analyzed.
Immunocytochemistry—3T3-L1 adipocytes were fixed in 4% paraformaldehyde (15
min), incubated with PBS containing 0.3% Triton-X-100 and 1% BSA (1 h at RT), and then
exposed to rabbit anti-GLUT4 antibody (1:100; Abcam, Cambridge, MA). After an
overnight incubation at 4°C, an anti-rabbit Alexa488-conjugat ed secondary antibody
(1:500; Invitrogen) was added. Samples were visualized under a Delta-Vision high-
resolution microscope (Applied Precision, Inc., Issaquah, WA). Image stacks were
deconvolved with Delta-Vision microscope software and analyzed with ImageJ software. To
evaluate the number of cells expressing GLUT4 at the plasma membrane, a ratio of the
number of cells that were stained for GLUT4 at the cell surface over the total number of
cells was calculated. A minimum of 650 cells per group was counted. Moreover, a minimum
of 90 cells positive for cell surface GLUT4 labeling per group was used to assess
quantitatively the effect of insulin on the amount of GLUT4 present at the plasma membrane
over total GLUT4 staining. Negative control samples without the primary antibody were
included to assess non-specific staining.
Enzyme-linked immunosorbent assay—Plasma or serum concentration of IL-6, TNF-
α, IL-1β, CRP, adiponectin and NEFA were determined in duplicate with commercially
available ELISA kits: IL-6, TNF-α and IL-1β (Cell Sciences, Inc., Canton, MA);
adiponectin (AdipoGen, Burlington, NC); CRP (USCN Life Science, Inc., Wuhan, China);
NEFA (Wako diagnostic, Richmond, VA).
Citrate synthase activity and hydrogen peroxide determination—Visceral
adipose tissue was homogenized in RIPA buffer supplemented with EDTA and EGTA
(Boston BioProducts), protease and phosphatase inhibitors (Sigma-Aldrich) and 0.1 mM
phenylmethylsulfonyl fluoride (Sigma-Aldrich). Citrate synthase was determined by
spectrophotometric methods in 20 μg of protein lysates following the method described by
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Bernier et al. (Bernier et al., 2011). Hydrogen peroxide was determined using an Amplex
Red hydrogen peroxide determination kit (Invitrogen).
Data analysis—In vitro data presented in the text, figures and tables are expressed as
mean ± SEM. The AUC was determined using GraphPad Prism (La Jolla, CA). Boxplot
graphs were generated using statistical software to detect outliers within each variable. The
repeated measures data was analyzed using a linear mixed-effects model. Fisher's exact test
right-tailed, Z-test, Independent-Samples t test, One-Way ANOVA and repeated measures
ANOVA (RM-ANOVA) were also used, as appropriate. P < 0.05 was considered
statistically significant. Full statistical analysis details are described in Supplemental
Material.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
• Resveratrol elicits transcriptional changes in visceral and subcutaneous WAT
• Resveratrol exerts anti-inflammatory effects in visceral WAT of HFS-fed
monkeys
• Resveratrol's anti-inflammatory effect coincides with improved insulin
sensitivity
• Adipocytes play a key role in the adaptations evoked by resveratrol
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Figure 1. see also Table S2 and Table S3. Resveratrol supplementation induces changes in gene
expression in two fat depots
(A) Gene expression profile from subcutaneous fat of rhesus monkeys fed for 2 years with a
high-fat, high-sugar diet (HFS) without or with resveratrol (Resv) supplementation
compared to standard diet-fed animals at baseline (SDb). (B) Heatmap of immune-related
GO Terms in subcutaneous fat depot. The Z-score of a given GO Term showed striking
difference when comparing Resv to HFS (Resv_HFS) vs. HFS to SDb (HFS_SDb). (C)
Gene expression profile from visceral fat of rhesus monkeys fed for 2 years with HFS diet +/
− Resv supplementation compared to SD-fed animals. (D) Venn diagram of overlapping
genes significantly changed in the comparison HFS_SD, Resv_HFS, and Resv_SD. (E)
Scatter plot of gene expression values in Resv_HFS vs. HSF_SD within the ‘stresspathway’
gene set. (A to E) SDb, n=2; SD, n=2; HFS diet, n=4 and HFS + Resv diet, n=4.
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Figure 2. see also Figure S3. Resveratrol decreases mean adipocyte size and increases SIRT1
protein expression in visceral WAT of rhesus monkeys maintained on HFS diet for 2 years
(A) Morphologic characteristics of subcutaneous WAT. (B) Morphologic characteristics of
visceral WAT. (C) SIRT1 protein levels in subcutaneous WAT. (D) SIRT1 protein levels in
visceral WAT. (A and B) H&E-stained sections of WAT from monkeys fed HFS and HFS +
Resv diet are shown. Images were captured at 20× magnification. Scale bar: 200 μm. Mean
adipocyte size and adipocyte frequency distribution show cell surface areas in both fat
depots after 24-mo of dietary intervention. (A to D) Results are expressed in a dot plot
format, which represents the individual data and the mean. (A) n=7 (HFS diet); n=8 (HFS +
Resv diet). (B) n=8 for each group. (C and D) n=10 for each group. The data were analyzed
using Independent-Samples t test to analyze statistical significance between HFS vs. HFS
+Resv diet at 24-mo of dietary intervention. *, P < 0.05 (HFS vs. HFS + Resv diet). HFS:
high-fat, high-sugar; Resv: resveratrol; VAT: visceral adipose tissue; SAT: subcutaneous
adipose tissue.
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Figure 3. see also Table S4 and Table S5. Resveratrol decreases inflammatory response in
visceral WAT of rhesus monkeys fed a HFS diet for 2 years
(A) IκBα protein levels in visceral WAT. (B) phosphorylated NF-κB/NF-κB ratio in
visceral WAT. (C) Acetylated NF-κB protein content in visceral WAT. IP with a control
IgG did not result in NF-κB detection (data not shown). (D) mRNA expression for IL-6,
TNF-α, IL-1β and adiponectin in visceral WAT. (E) IκBα protein levels in subcutaneous
WAT. (F) Phosphorylated NF-κB/NF-κB ratio in subcutaneous WAT. (A to F) Results are
expressed in a dot plot format, which represents the individual data and the mean. (A and E)
n=10 for each group. (B) n=9 (HFS diet); n=8 (HFS + Resv diet). (C) n=10 (HFS diet); n=9
(HFS + Resv diet). (D) IL-6 and IL-1β: n=8 (HFS diet); n=10 (HFS + Resv diet). TNF-α and
adiponectin: n=7 (HFS diet); n=10 (HFS + Resv diet). (F) n=9 (HFS diet); n=10 (HFS +
Resv diet). (A to F) The data were analyzed using Independent-Samples t test to analyze
statistical significance between HFS vs. HFS + Resv diet at 24-mo of dietary intervention.
IL-1β gene expression was log-transformed before statistical analysis. *, P < 0.05 (HFS vs.
HFS + Resv diet). HFS: high-fat, high-sugar; Resv: resveratrol; VAT: visceral adipose
tissue; SAT: subcutaneous adipose tissue; pNF-κB: phosphorylated NF-κB.
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Figure 4. see also Figure S1. Resveratrol improves insulin sensitivity in visceral WAT of rhesus
monkeys fed a HFS diet for 2 years
(A) IRS-1 protein expression. (B) Phosphorylated Akt/Akt ratio. (C) GLUT4 protein levels.
(D) TUG protein content. (A to D) Results are expressed in a dot plot format, which
represents the individual data and the mean. (A) n=8 (HFS diet); n=10 (HFS + Resv diet).
(B) n=9 (HFS diet); n=10 (HFS + Resv diet). (C and D) n=10 (HFS diet); n=9 (HFS + Resv
diet). The data were analyzed using Independent-Samples t test to analyze statistical
significance between HFS vs. HFS + Resv diet at 24-mo of dietary intervention. *, P < 0.05
(HFS vs. HFS + Resv diet). HFS: high-fat, high-sugar; Resv: resveratrol; VAT: visceral
adipose tissue; pAkt: phosphorylated Akt.
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Figure 5. Serum from resveratrol-treated monkeys on HFS diet exerts anti-inflammatory effects
in 3T3-L1 adipocytes
Fully-differentiated 3T3-L1 adipocytes were incubated for 24-h with media containing
serum from SD and HFS +/− Resv diet-fed monkeys for 2 years. (A) SIRT1 protein levels.
(B) IκBα protein levels. (C) Phosphorylated NF-κB/NF-κB ratio. Lanes were run on the
same gel but were noncontiguous. (D) mRNA expression for IL-6, TNF-α, IL-1β and
adiponectin. (A to D) The graphs show the mean ± SEM from 3 independent experiments,
and the results are expressed as percent increase over the values observed in adipocytes
treated with HFS serum. The data were analyzed using One-Way ANOVA. *, P < 0.05 (HFS
vs. HFS + Resv serum); #, P < 0.05 (HFS vs. SD serum). SD: standard diet; HFS: high-fat,
high-sugar; Resv: resveratrol; pNF-κB: phosphorylated NF-κB.
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Figure 6. Serum from resveratrol-treated monkeys on HFS diet improves insulin signaling in
3T3-L1 adipocytes
(A) IRS-1 protein levels in 3T3-L1 adipocytes incubated for 24-h with media containing
serum from SD and HFS +/− Resv diet-fed monkeys for 2 years (n=3). Lanes were run on
the same gel but were noncontiguous. (B) Phosphorylated Akt/Akt ratio in 3T3-L1
adipocytes pretreated for 24-h with media containing serum from SD and HFS +/− Resv
diet-fed monkeys for 2 years and stimulated with insulin (100 nM) for 10, 20 and 30 min
(n=3). (C) Number of cells expressing GLUT4 at the plasma membrane. 3T3-L1 adipocytes
were incubated for 24-h with media containing serum from SD and HFS +/− Resv diet-fed
monkeys for 2 years and then treated in the absence (0 min) or presence of 100 nM insulin
(30 min). GLUT4-labeled sections of 3T3-L1 adipocytes are shown. Images were captured
at 10× magnification. Scale bar: 90 μm. The number of cells that were stained for GLUT4 at
the plasma membrane over total cell number both in control and insulin-treated cells were
counted (n=5). (D) Insulin-induced cell surface GLUT4 labeling. 3T3-L1 adipocytes were
pretreated for 24-h with media containing serum from SD and HFS +/− Resv diet-fed
monkeys for 2 years and then stimulated with insulin (100 nM) for 30 min. GLUT4-labeled
sections of 3T3-L1 adipocytes are shown. Images were captured at 60× magnification. Scale
bar: 15 μm. The amount of GLUT4 labeling at the plasma membrane of insulin-treated cells
was normalized by the total GLUT4 staining in the same cells (n=5). (A to D) The graphs
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show the mean ± SEM, and the results are expressed as percent increase over the values
observed in adipocytes treated with HFS serum (A and D) or as percent increase over the
values observed in adipocytes at baseline (B and C). The data were analyzed using One-Way
ANOVA and RM-ANOVA was used to calculate the time effect (P time), the diet effect (P
diet) and the diet × time interaction (P diet × time). *, P < 0.05 (HFS vs. HFS + Resv
serum); #, P < 0.05 (HFS vs. SD serum). SD: standard diet; HFS: high-fat, high-sugar; Resv:
resveratrol; pAkt: phosphorylated Akt; PM: plasma membrane.
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Table 1
Monkey characteristics after dietary interventiona,b.
SDb HFS diet HFS + Resv diet P value
N 24 10 10
Waist, cm 41.06±2.03* 55.95±5.93 53.05±3.28 <0.001
Hips, cm 39.07±1.31* 50.16±3.20 48.60±1.83 <0.001
Total Cholesterol, mg/dL 141.87±6.01 162.40±19.48 159.30±12.18 0.103
LDL-C, mg/dL 57.54±12.55# 84.20±13.84 73.00±6.59 0.008
HDL-C, mg/dL 71.67±4.31 58.60±7.80 63.90±7.57 0.037
NEFA, mEq/L 0.83±0.08 0.64±0.06 0.54±0.06 0.068
See also Table S1 and Figure S2.
aValues are presented as mean ± SEM. The data were analyzed using using a linear mixed-effects model Hips: n=24 (SDb); n=9 (HFS diet); n=10
(HFS + Resv diet). SDb: Standard diet baseline; HFS: High-fat, high-sugar; Resv: Resveratrol.
*P ± 0.05 SDb vs. HFS ± Resv diet
#P = 0.011 SDb vs. HFS diet.
b
Blood samples were obtained from fasting animals.
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